Cite as: 564 U. S. ____ (2011)

1

SOTOMAYOR, J., dissenting

SUPREME COURT OF THE UNITED STATES
_________________

Nos. 09–993, 09–1039, and 09–1501
_________________

09–993

PLIVA, INC., ET AL., PETITIONERS
v.
GLADYS MENSING

ACTAVIS ELIZABETH, LLC, PETITIONER
09–1039
v.
GLADYS MENSING

09–1501

ACTAVIS, INC., PETITIONER
v.
JULIE DEMAHY

ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF
APPEALS FOR THE EIGHTH AND FIFTH CIRCUITS
[June 23, 2011]

JUSTICE SOTOMAYOR, with whom JUSTICE GINSBURG,
JUSTICE BREYER, and JUSTICE KAGAN join, dissenting.
The Court today invokes the doctrine of impossibility
pre-emption to hold that federal law immunizes generic
drug manufacturers from all state-law failure-to-warn
claims because they cannot unilaterally change their la
bels. I cannot agree. We have traditionally held defen
dants claiming impossibility to a demanding standard:
Until today, the mere possibility of impossibility had not
been enough to establish pre-emption.
The Food and Drug Administration (FDA) permits—
and, the Court assumes, requires—generic-drug manufac
turers to propose a label change to the FDA when they
believe that their labels are inadequate. If it agrees that
the labels are inadequate, the FDA can initiate a change

